PMID- 31188048
OWN - NLM
STAT- MEDLINE
DCOM- 20200430
LR  - 20200430
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Linking)
VI  - 11
IP  - 10
DP  - 2019 Jul
TI  - The interaction of immune checkpoint inhibitor plus chemotherapy in 
      non-small-cell lung cancer: subadditivity, additivity or synergism?
PG  - 913-920
LID - 10.2217/imt-2019-0014 [doi]
AB  - The hypothesis that the interaction of chemotherapy and immune checkpoint 
      inhibitors (ICIs) is synergistic has not been formally validated. The frontline 
      ICI Phase II/III trials in advanced non-small-cell lung cancer were reviewed for 
      the objective response rates (ORRs) and grade 3-5 adverse events (AEs) of 
      ICI-chemotherapy combinations and those of each individual drug. The expected ORR 
      and grade 3-5 AE of ICI-chemotherapy combinations were computed as the arithmetic 
      sum of the pooled effects of each drug. Statistical pooling was performed using a 
      double arcsine transformation and a random-effects model. Our findings suggest an 
      enhanced effect that is less than additive for the ICI-chemotherapy combinations 
      since the actual ORR and grade 3-5 AE were found to be less than the expected 
      additive effect.
FAU - Rassy, Elie
AU  - Rassy E
AD  - Department of Hematology-Oncology, Hotel Dieu de France University Hospital, 
      Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
FAU - Bakouny, Ziad
AU  - Bakouny Z
AD  - Department of Hematology-Oncology, Hotel Dieu de France University Hospital, 
      Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
FAU - Assi, Tarek
AU  - Assi T
AD  - Department of Medical Oncology, Institut Gustave Roussy, Villejuif F-94805, 
      France.
FAU - Karak, Fadi El
AU  - Karak FE
AD  - Department of Hematology-Oncology, Hotel Dieu de France University Hospital, 
      Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
FAU - Pavlidis, Nicholas
AU  - Pavlidis N
AD  - University of Ioannina, Ioannina, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190612
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - *Carcinoma, Non-Small-Cell Lung/immunology/mortality/therapy
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - *Immunotherapy
MH  - *Lung Neoplasms/immunology/mortality/therapy
MH  - Male
OTO - NOTNLM
OT  - additive
OT  - chemotherapy
OT  - immune checkpoint inhibitor
OT  - non-small-cell lung cancer
OT  - synergistic
EDAT- 2019/06/13 06:00
MHDA- 2020/05/01 06:00
CRDT- 2019/06/13 06:00
PHST- 2019/06/13 06:00 [pubmed]
PHST- 2020/05/01 06:00 [medline]
PHST- 2019/06/13 06:00 [entrez]
AID - 10.2217/imt-2019-0014 [doi]
PST - ppublish
SO  - Immunotherapy. 2019 Jul;11(10):913-920. doi: 10.2217/imt-2019-0014. Epub 2019 Jun 
      12.